Transthyretin Amyloidosis (ATTR) Market Research Report – Forecast to 2027

Transthyretin (TTR) Amyloidosis Market Information: Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), & End-User (Ambulatory Surgical Center, Clinics) – Global Forecast Till 2027

ID: MRFR/Pharma/4697-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.


Research Methodology:


 Transthyretin (TTR) Amyloidosis Market


Source: World Health Organization, Centers for Disease Control and Prevention, American Heart Association, National Institute of Health, American College of Cardiology, European Heart Network, expert interview, annual report, white paper, company presentation and market research future analysis


Market Players



  • Alnylam Pharmaceuticals

  • Pfizer

  • Merck

  • Ionis Pharmaceuticals Inc.

  • Corino Therapeutics Inc

  • Arcturus Therapeutics

  • Proclara Bioscience


Market Segmentation                                                                                                                          


The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.


Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.


Regional Market Summary


Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.


Europe is the second largest market and holds a healthy share in the global Transthyretin (TTR) amyloidosis market. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.


Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.


Global Transthyretin (TTR) Amyloidosis Market Share (%), by Region, 2017


 Transthyretin (TTR) Amyloidosis Market Share


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Market Segmentation


Global Transthyretin (TTR) Amyloidosis Market, by Disease Type       



  • Transthyretin (TTR) Familial Amyloid Polyneuropathy

  • Transthyretin (TTR) Familial Amyloid Cardiomyopathy

  • Others


Global Transthyretin (TTR) Amyloidosis, by Treatment



  • Small molecules treatment

    • Tafamidis

    • Diflunisal



  • RNAi therapy

  • Organ Transplantation


Global Transthyretin (TTR) Amyloidosis Market, by Gender                                



  • Male

  • Female


Global Transthyretin (TTR) Amyloidosis Market, by End-User



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Others


Global Transthyretin (TTR) Amyloidosis Market, by Region


North America



  • U.S.

  • Canada


South America


Europe



  • Western Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe


Asia Pacific



  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific


Middle East and Africa



  • United Arab Emirates

  • Saudi Arabia

  • Oman

  • Kuwait

  • Qatar

  • Rest of the Middle East & Africa


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Frequently Asked Questions (FAQ) :


Major types of Transthyretin Amyloidosis include transthyretin (TTR) familial amyloid polyneuropathy, transthyretin (TTR) familial amyloid cardiomyopathy, and others.

Major treatments used for transthyretin amyloidosis include small molecule treatment, RNAi therapy, and organ transplantation.

The rising number of drug launches in the market is a key driver for the Transthyretin Amyloidosis Market.

The Americas dominate the global Transthyretin Amyloidosis Market.

Leading players in the Transthyretin Amyloidosis Market include Pfizer, Merck, and Ionis Pharmaceuticals, among others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Transthyretin (TTR) Amyloidosis, by Disease Type

6.1 Introduction

6.2 Transthyretin (TTR) Familial Amyloid Polyneuropathy

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.3 Transthyretin (TTR) Familial Amyloid Cardiomyopathy

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.4 Others

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

7. Global Transthyretin (TTR) Amyloidosis, by Treatment

7.1 Introduction

7.2 Small molecules treatment

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.2.1Tafamidis

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.2.2 Diflunisal

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3 RNAi therapy

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.4 Organ Transplantation

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.5 Others

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8. Global Transthyretin (TTR) Amyloidosis, by Gender

8.1 Introduction

8.2 Male

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.3 Female

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9. Global Transthyretin (TTR) Amyloidosis, by End-User

9.1 Introduction

9.2 Ambulatory Surgical Centers

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.3 Hospitals & Clinics

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.4 Others

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

10 Global Transthyretin (TTR) Amyloidosis, by Region

10.1 Introduction

10.2 Americas

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1 North America

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.1 U.S.

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.2 Canada

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.2 South America

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3 Europe

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1 Western Europe

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease Type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.1 Germany

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.2 France

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.3 U.K.

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender , 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.4 Italy

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender , 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.5 Spain

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.6 Rest of Western Europe

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.2 Eastern Europe

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4 Asia Pacific

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.1 Japan

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.2 China

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.3 India

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.4 Australia

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.5 Republic of Korea

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.6 Rest of Asia Pacific

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5 The Middle East & Africa

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.1 United Arab Emirates

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.2 Saudi Arabia

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.3 Oman

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.4 Kuwait

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.5 Qatar

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.6 Rest of the Middle East & Africa

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Pfizer

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Merck

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Alnylam Pharmaceuticals

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Ionis Pharmaceuticals Inc.

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Corino Therapeutics Inc

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Proclara Bioscience

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Arcturus Therapeutics

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of the Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Transthyretin (TTR) (TTR) amyloidosis Industry Synopsis, 2020–2027

Table 2 Global Transthyretin (TTR) Amyloidosis Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Transthyretin (TTR) Amyloidosis, by Region, 2020–2027, (USD Million)

Table 4 Global Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 5 Global Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 6 Global Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 7 Global Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 8 North America Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 9 North America Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 10 North America Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 11 North America Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 12 US Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 13 US Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 14 US Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 15 US Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 16 Canada Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 17 Canada Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 18 Canada Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 19 Canada Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 20 South America Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 21 South America Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 22 South America Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 23 Europe Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 24 Europe Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 25 Europe Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 26 Western Europe Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 27 Western Europe Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 28 Western Europe Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 29 Eastern Europe Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 30 Eastern Europe Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 31 Eastern Europe Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 32 Asia Pacific Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 33 Asia Pacific Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 34 Asia Pacific Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 35 Middle East & Africa Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 36 Middle East & Africa Transthyretin (TTR) Amyloidosis, by diagnoses, 2020–2027, (USD Million)

Table 37 Middle East & Africa Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Transthyretin (TTR) Amyloidosis

Figure 3 Segmentation Market Dynamics for Transthyretin (TTR) Amyloidosis

Figure 4 Global Transthyretin (TTR) Amyloidosis Share, by Disease type 2020

Figure 5 Global Transthyretin (TTR) Amyloidosis Share, by Treatment 2020

Figure 6 Global Transthyretin (TTR) Amyloidosis Share, by End-Users, 2020

Figure 7 Global Transthyretin (TTR) Amyloidosis Share, by Region, 2020

Figure 8 North America Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 9 Europe Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 10 Asia Pacific Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 11 Middle East & Africa Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 12 Global Transthyretin (TTR) Amyloidosis: Company Share Analysis, 2020 (%)

Figure 13 Arcturus Therapeutics: Key Financials

Figure 14 Arcturus Therapeutics: Segmental Revenue

Figure 15 Arcturus Therapeutics: Geographical Revenue

Figure 16 Merck. Key Financials

Figure 17 Merck: Segmental Revenue

Figure 18 Merck: Geographical Revenue

Figure 19 Alnylam Pharmaceuticals: Key Financials

Figure 20 Alnylam Pharmaceuticals: Segmental Revenue

Figure 21 Alnylam Pharmaceuticals: Geographical Revenue

Figure 22 Ionis Pharmaceuticals Inc.: Key Financials

Figure 23 Ionis Pharmaceuticals Inc.: Segmental Revenue

Figure 24 Ionis Pharmaceuticals Inc.: Geographical Revenue

Figure 25 Corino Therapeutics Inc: Key Financials

Figure 26 Corino Therapeutics Inc: Segmental Revenue

Figure 27 Corino Therapeutics Inc.: Geographical Revenue

Figure 28 Merck. Key Financials

Figure 29 Merck. Segmental Revenue

Figure 30 Merck. Geographical Revenue

Figure 31 Pfizer Key Financials

Figure 32 Pfizer Segmental Revenue

Figure 33 Pfizer Geographical Revenue